Validation of a 46-Gene CCP RNA Signature for Predicting Prostate Cancer Death
Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Clinical Pearls
Peter T. Scardino, MD, FACS, Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
- Prolaris measures change in RNA expression levels of multiple genes related to the progression of tumor cell division.
- This analysis looked to determine if changes in CCP score added to stage, grade, PSA, and extent of disease with regard to the informed management of disease.
- The endpoint of this analysis was not changes in pathology or Gleason score, but rather patients’ risk of developing metastases and dying of disease.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Cusnir Explores Impact of ARANOTE Data on ARPI Plus ADT Use in mHSPC
December 31st 2024During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
